The geopolitical shock from the Middle East conflict is rippling well beyond oil markets — and into hospital radiology departments.
The escalation of conflict involving Iran and mounting pressure on shipping through the Strait of Hormuz have tightened global supply chains for a range of industrial gases. Among them is helium — a niche commodity essential to parts of the healthcare system, central to the cooling systems that keep MRI machines operational.
As energy markets surge and logistics through the Persian Gulf become more complex, helium prices are climbing again, reviving concerns about availability just as healthcare systems remain stretched.
A fragile supply chain meets geopolitical risk
Helium has long been a structurally tight market. Production is concentrated in a handful of regions — notably the US, Qatar and Algeria — with much of the world’s supply moving through shipping routes exposed to geopolitical disruption.
That fragility has been highlighted repeatedly over the past decade through periodic shortages. But the current situation carries a sharper edge.
Helium is largely produced as a byproduct of natural gas processing, tying its supply closely to LNG markets. That makes major producers like Qatar — and export routes linked to the Strait of Hormuz — particularly important to global availability.
The helium market is also sensitive to even minor disruptions, with limited storage capacity and long lead times for new supply. The latest escalation adds a new layer of uncertainty, particularly as conflict dynamics broaden across the region.
At the same time, rising energy prices are feeding directly into helium production costs, given its link to natural gas processing. The result is a dual squeeze: tighter supply and higher prices.
Why MRI machines are especially exposed
For healthcare providers, the most immediate concern sits inside MRI suites.
Magnetic resonance imaging relies on superconducting magnets that must be cooled to extremely low temperatures — a process that depends on liquid helium. While modern MRI systems are more efficient than older designs, they still require helium both for initial cooling and, in many cases, ongoing top-ups.
That makes helium not just an input cost, but a functional necessity.
When supply tightens, the impacts can cascade:
- Rising operating costs for imaging providers, particularly in private radiology networks
- Delayed maintenance or refilling, increasing the risk of system downtime
- Deferred installations of new MRI units due to higher up-front costs and uncertainty around long-term supply
Recent industry coverage suggests imaging providers are already monitoring the situation closely, wary of a repeat of past shortages that forced rationing and operational adjustments.
In extreme cases, a loss of helium cooling — known as a “quench” — can take an MRI machine offline entirely, requiring costly and time-consuming remediation.
Beyond imaging: A wider healthcare footprint
MRI is the most visible pressure point, but helium’s role in healthcare extends further.
It is used in:
- Cryogenics and laboratory research, including biobanking and sample preservation
- Medical device manufacturing, where inert gas environments are required
- Respiratory treatments, in the form of helium-oxygen mixtures for certain conditions
That broader footprint means price spikes can filter through multiple parts of the healthcare value chain, from hospital operations to biotech R&D.
For smaller biotech companies in particular — already navigating tight funding conditions — incremental cost pressures on lab operations can be material.
A market signal — and a strategic opportunity
The renewed helium squeeze is both a warning and a signal for investors. On one hand, it reinforces how exposed critical healthcare infrastructure can be to seemingly peripheral commodities. Helium may represent a small fraction of total costs, but it is indispensable — a classic bottleneck input.
On the other, it sharpens the strategic case for new supply.
Companies exploring or developing helium resources, including several listed on the ASX, such as D3 Energy Ltd (ASX:D3E, OTCQX:DNRGF), have increasingly framed their projects around supply security rather than just price upside. The latest geopolitical shock strengthens that narrative.
It also raises longer-term questions about substitution and efficiency. MRI manufacturers have made progress in reducing helium usage, including the development of “zero boil-off” systems and lower-fill magnets. But widespread adoption takes time — and does not eliminate dependence entirely.
Watching the next phase
For now, much hinges on how the Middle East situation evolves.
If shipping through Hormuz stabilises, the current price spike may prove temporary. But if disruptions persist — or continue broadening to other key routes such as the Red Sea, where Houthi militants opened a new front over the weekend — the helium market could tighten further.
For healthcare providers, that means contingency planning is back in focus. For investors, it is another reminder that in biotech and medtech, the supply chain doesn’t stop at molecules and devices — it runs all the way down to the gases that keep them working.